Alexandr Wang, the 28-year-old Scale AI founder now heading to Meta Platforms’ (NASDAQ:META) new "super-intelligence" lab says artificial-intelligence models already possess insights that science cannot match and that makes it “a strange time to be a scientist, but an exciting time for science.”
What Happened: Wang told a Y Combinator audience the advantage is clearest in biology, where “there's probably intuitions that the models have about biology that humans don't even have because they have this different form of intelligence.”
He narrated a story that predicted AI systems will soon run "all the frontiers of R&D," leaving human researchers to "look at the discoveries the AIs make and try to understand them."
The comments arrive days after Meta paid about $14 billion for a 49% stake in Scale and hired Wang to accelerate Mark Zuckerberg's push for artificial general intelligence.
"Areas like biology will fuel breakthroughs in medicine and healthcare," Wang said, adding that the rest of the economy will "chug along giving humans what they want."
Why It Matters: Venture investors share that view. CB Insights counts 370 AI-biology startups worth a combined $60 billion, up 28% from 2023.
Even though critics warn dual-use risks rise as models master bio-engineering, prompting calls for guardrails even inside Meta's lab, Wang argues embracing the shift is essential.
Photo Courtesy: Gorodenkoff on Shutterstock.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
